Aberrant glycosylation is a hallmark of cancer progression. The discovery of tumor-associated carbohydrate antigens (TACAs) by Dr. Sen-Itiroh Hakomori has raised active pursuit of glycan-targeting therapeutics and diagnostics. GlycoNex owns a bank of glycan-specific monoclonal antibodies (mAbs) with specificity to various tumor-associated carbohydrate antigens. Traditional chemotherapy would cause severe side effects to patients. To overcome the disadvantage, antibody has become a promising target therapy with superior selectivity to differentiate cancer cells from normal tissues by recognizing tumor markers, which could significantly improve the life span and quality of cancer patients. GlycoNex is dedicated to development of glycan-directed immunotherapy by applying our promising anti-glycan mAbs and the combination with potential regimens.

The heterogeneity and complexity of cellular glycans are often the bottlenecks of glycan-directed therapeutic and diagnostic strategies. GlycoNex has established an analytical platform combining liquid/ion chromatography, mass spectrometry, and antibody reagents (GlycoBind) for complete characterization of glycans from biologics and biological samples. The versatile glycan analytical platform empowers GlycoNex to be highly advantageous in development of glycan-directed cancer therapy and biosimilar.